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Abstract
Corticotropin-releasing factor (CRF) signaling pathways are involved in the stress response, and there is growing evidence
supporting hair growth inhibition of murine hair follicle in vivo upon stress exposure. We investigated whether the blockade
of CRF receptors influences the development of hair loss in CRF over-expressing (OE)-mice that display phenotypes of
Cushing’s syndrome and chronic stress, including alopecia. The non-selective CRF receptors antagonist, astressin-B (5 mg/
mouse) injected peripherally once a day for 5 days in 4–9 months old CRF-OE alopecic mice induced pigmentation and hair
re-growth that was largely retained for over 4 months. In young CRF-OE mice, astressin-B prevented the development of
alopecia that occurred in saline-treated mice. Histological examination indicated that alopecic CRF-OE mice had hair follicle
atrophy and that astressin-B revived the hair follicle from the telogen to anagen phase. However, astressin-B did not show
any effect on the elevated plasma corticosterone levels and the increased weights of adrenal glands and visceral fat in CRF-
OE mice. The selective CRF2 receptor antagonist, astressin2-B had moderate effect on pigmentation, but not on hair re-
growth. The commercial drug for alopecia, minoxidil only showed partial effect on hair re-growth. These data support the
existence of a key molecular switching mechanism triggered by blocking peripheral CRF receptors with an antagonist to
reset hair growth in a mouse model of alopecia associated with chronic stress.
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Introduction
More than half a century ago, Hans Selye, the father of the
stress concept in biology, stated that ‘‘an intense psychic shock
may also exert pronounced effects on the hair, e.g., graying and
generalized loss of hair’’ [1]. Subsequent cumulative experimental
and clinical evidence indicates indeed, that chronic stress exerts a
profound inhibitory effect on hair growth [2–5]. Corticotropin-
releasing factor (CRF), adrenocorticotropic hormone (ACTH) and
glucocorticoids not only are key components of the endocrine and
neuroimmune responses to stress but also they interrupt hair
follicle growth cycle in humans and mice [2,3,6,7]. In cultured
human scalp hair follicles, CRF up-regulates transcription of pro-
opiomelanocortin (POMC) and immunoreactivity of ACTH and
a-melanocyte-stimulating hormone (MSH), and increases cortisol
secretion [5]. Slominski et al. [8,9] have also shown that CRF,
urocortin 1 and CRF receptor subtypes 1 and 2 (CRF1 and CRF2)
are expressed in the normal skin and cycling hair follicles of
humans and mice.
Mice that over-express CRF (CRF-OE) have been character-
ized as a model of chronic stress that captures phenotypes of
behavioral, endocrine, immunological, autonomic and visceral
alterations beside Cushing’s syndrome manifestations [10–16].
While a number of mouse mutants generated by targeting specific
pathways involving hair follicle cycle resulted in nude mice or
models of inflammatory alopecia [4,17,18], the CRF-OE mouse
has not been examined so far as a model relevant to chronic stress-
induced alopecia, despite an initial report that CRF-OE mice
develop bilateral symmetric hair loss in adulthood [11].
Based on existing evidence that chronic stress impairs hair growth
and that major components of the CRF system are expressed in the
mouse and human skin [9,19], we investigated the ability of CRF
receptor antagonists to influence hair loss/re-growth in CRF-OE
mice. We assessed whether blocking CRF receptors by short-term
peripheral treatment with the long acting peptide CRF1/CRF2
receptors antagonist, astressin-B [20] would induce hair re-growth
and pigmentation in adult alopecic CRF-OE mice and prevent the
development of alopecia in young CRF-OE mice. We also
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growth or whether it would also affect elevated plasma corticosterone
levels and other Cushing-like phenotypes (such as hypertrophy of the
adrenal glands and increased adipose deposits) [11]. Lastly, we tested
under similar conditions whether the selective CRF1 receptor non
peptide antagonist, NBI 27914 [21], the selective CRF2 receptor
peptide antagonist, astressin2-B [22] or a commercial drug, minoxidil
[23] exert effects on hair growth and pigmentation.
Results
The non-selective CRF1/CRF2 antagonist, astressin-B
injected intraperitoneally (ip) or subcutaneously (sc)
reverses alopecia in CRF-OE mice
Male and female CRF-OE mice develop alopecia when they are
older than 4 months. Saline injected ip in male CRF-OE mice did not
have any effect on the alopecia: the skin color remained pink and no
hair grew throughout the monitoring period (Figs. 1A and 2A, B). By
contrast, the CRF1/CRF2 receptor antagonist, astressin-B injected ip
at 5 mg/mouse once a day for 5 consecutive days resulted in the
development of dark pigment on the initiallypink alopecic skin within
3 days after the last injection in 4 months old male CRF-OE mice
(Fig. 1B). Simultaneously, as the pigment increased to a maximal
response within 7–10 days (Fig. 2A), hairs sprouted out and grew to
full length with 95–100% of hair coverage in 2 weeks (Figs. 1C and
2B). The re-grown hair was retained for the following 8 weeks
(Fig. 2B), and then largely maintained up to 4 months post injection
when mice were euthanized (data not shown). Similarly, astressin-B
(5 mg/mouse) injected sc once a day for 5 days induced skin pigment
within one week after the last injection in 80% of the 4–9 months old
alopecic female and male CRF-OE mice (Fig 3B, G). Mice regained
50–90% hair coverage at 2–4 weeks post treatment (Fig. 3A–C, H).
In contrast, sc injection of astressin2-B (5 mg/mouse once a day
for 5 consecutive days) did not induce hair growth in CRF-OE
mice (Fig. 3E–H) although a low grade but significant pigmenta-
tion occurred (Fig. 3G). Likewise, the CRF1 antagonist, NBI
27914 (0.5 mg/mouse) injected sc twice a day for 5 days in 5
months old female CRF-OE mice did not induce any hair re-
growth (data not shown).
Skin morphological changes in CRF-OE mice injected
intraperitoneally with astressin-B
Histological assessment showed that the hair follicles in the
alopecic skin from CRF-OE mice (7 months old, male) injected ip
Figure 1. The CRF1/CRF2 receptor antagonist, astressin-B, injected intraperitoneally (ip) in CRF-OE mice with fully developed
alopecia induces hair growth and pigmentation. Photographs: Row A: Male CRF-OE mice (4 months old) injected ip once daily for 5
consecutive days with saline at 3 days after the last injection and Row B: astressin-B (5 mg/mouse) at 3 days after the last ip injection, and Row C: the
same mice as in the middle panel Row B at 4 weeks after the last ip injection.
doi:10.1371/journal.pone.0016377.g001
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the WT littermates (Fig. 2C). The length of the hair follicle in
CRF-OE mice was significantly shorter than that in the WT
(0.3760.03 vs. 0.5460.03 mm; n=5/group; P,0.05). In ip
astressin-B-treated CRF-OE mice, hair follicle reformation was
seen 2 weeks after the treatment (Fig. 2E) and the hair follicles
were changed from the telogen to anagen phase (Fig. 2D, E). The
average length of the hair follicles was 0.4260.05 mm (n=5) and
no longer significantly different from those in WT littermates.
Lack of effect of intraperitoneal astressin-B on other
features of Cushing’s syndrome in CRF-OE mice
CRF-OE mice (4–7 months old, female) had a significant 3.9
times higher plasma corticosterone levels than WT littermates as
assessed at day 7 after the last ip saline injection (Fig. 4A).
Astressin-B (5 mg/mouse) injected ip for 5 days reversed alopecia
but did not modify the elevated plasma corticosterone levels in
CRF-OE mice at any of the days monitored, i.e, days 1, 3, 7 and
14 after the last ip astressin-B injection (Fig. 4A). In addition, the
weights of adrenal glands and visceral fat were significantly greater
in CRF-OE than in WT mice, and unchanged by ip astressin-B
injections as monitored on days 7 and 14 after the last peptide
injection (Fig. 4B, C).
Astressin-B given subcutaneously in young CRF-OE mice
prevents development of alopecia
Young CRF-OE mice (7–8 weeks of age, female) with little hair
loss injected sc with saline developed alopecia in 70–100% area of
the back during the 8–16 weeks after injection (Fig. 5J). By
contrast, young CRF-OE mice injected sc with astressin-B (5
mg/mouse/day for 5 days) displayed skin pigmentation within one
week after the last injection (Fig. 5I), did not have hair loss from
the back for the following 2 months and kept on average 70% of
the hair at the end of the 4 months observation period post
injection (Fig. 5A–D, J). On the other hand, sc astressin2-B-
injected CRF-OE mice showed a moderate induction of skin
pigment during the first week post injection (Fig. 5I), but continued
to lose hair similarly as the saline-treated mice (Fig. 5.E–H, J).
Effect of minoxidil given subcutaneously to CRF-OE mice
with alopecia
The administration of 1% minoxidil sulfate solution (0.1 ml/
mouse, sc) once a day for 10 days in 5 months old female alopecic
CRF-OE mice induced patches of pigment 2 weeks after the last
injection in 3 out of the 4 treated CRF-OE mice and a moderate
hair growth in the pigmented patches was observed at 2 and 4
weeks after the last injection while vehicle injection had no effect
(Fig. 6).
Discussion
The present experiments demonstrate that, in the CRF-OE mice
with alopecia, blockade of both CRF1 and CRF2 receptors with
intraperitoneal or subcutaneous injection of the peptide CRF1 and
CRF2 receptor antagonist, astressin-B [20] induces a robust skin
pigmentation and hair re-growth. In addition, in young not yet
alopecic CRF-OE mice, astressin-B prevents hair loss. Remarkably,
the hair re-growth was observed with as little as 5 daily single
injections of 5 mg/mice. This study also provides evidence that CRF-
OE mice display features of a relevant model to study alopecia.
Figure 2. Skin pigment score (A), hair growth score (B) and skin photomicrographs (C–E) of male CRF-OE mice (7 months old)
injected ip once a day for 5 consecutive days with astressin-B (5 mg/mouse) or saline. Data are individual and median in A and mean 6
SEM in B, p,0.05 vs before the ip injection. Photomicrographs show the hair follicle morphology (scale 100 mm) in the back skin of male wild type
mice (C) and CRF-OE mice at 2 weeks after the last ip injection of saline (D) or astressin-B (E). Arrows indicate a hair follicle in each panel.
doi:10.1371/journal.pone.0016377.g002
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that are expressed in murine skin including hair follicles [8,24]. This
is supported by the data that neither the long acting selective CRF2
antagonist, astressin2-B [22] nor the selective CRF1 antagonist, NBI
27914 [21] given alone had effect on hair growth when
administered subcutaneously at doses blocking exogenous CRF or
urocortin 1 actions [22,25]. Similarly, in young CRF-OE mice,
subcutaneous injection of astressin-B prevented the development of
alopecia in the subsequent several weeks/months monitoring time.
However, saline and astessin2-B treated CRF-OE mice developed
full alopecia although selective blockade of CRF2 receptors by
astessin2-B, resulted in mild and brief increased pigmentation.
Additional research is needed to assess the respective role of CRF
receptor subtypes onhairre-growth and pigmentation. In particular
whether different dosing regimens of CRF1- or CRF2-selective
antagonists induce measurable effects on hair growth and
pigmentation as well as identification of molecule(s) and cells on
which astressin-B acts to trigger its effects require further studies.
Regardless, the present data provide the first evidence of the
potency and efficacy of astressin-B injected peripherally to induce a
long term reversal or prevention of alopecia in CRF-OE mice.
These murine data are also in line with the effect of CRF agonists
and antagonists on human hair follicle elongation [5].
Because astressin-B was injected peripherally in CRF-OE mice, it
ispossiblethat the observedeffectmayhaveresultednotonlyfrom a
local action but also through decreasing the deleterious effects that
chronic systemic activation of the pituitary and adrenal secretion
may have on skin pigmentation and hair re-growth [2,3]. Indeed,
adrenalectomy was shown to reverse alopecia in CRF-OE mice
[11]. However, in the present study we did not detect changes in the
elevated corticosterone plasma levels in CRF-OE mice at each time
point monitored on days 1, 3, 7 and 14 after the end of astressin-B
treatment. These data are consistent with our previous pharmaco-
kinetic studies showing that under chronic stimulation of the
hypothalamic-pituitary axis, astressin-B injected peripherally
blocked the elevated ACTH plasma levels for 12 h while at 24 h
post injection values are back to those of vehicle [20]. In addition,
the CRF antagonist was given as a single injection once a day for
only 5 days and yet the re-grown hair in most of the mice was
maintained for up to several months. The prevention of hair loss
was still remarkable 3 to 4 months post treatment. Therefore,
although the ablation of the adrenals reversed the alopecia in CRF-
OE mice [11], the fact that astressin-B, at the regimen used, exerted
such dramatic effect against the alopecia without affecting plasma
corticosterone levels rules out the possibility that peripheral
injection of astressin-B exerts a persistent inhibition of the ACTH-
Figure 3. Subcutaneous (sc) injection of CRF1/CRF2 receptor antagonist, astressin-B induces pigmentation and hair growth in CRF-
OE mice with alopecia. Groups of 6–9 month old male or female CRF-OE mice were injected sc once daily for 5 consecutive days either with
astressin-B (5 mg/mouse) or astressin2-B (5 mg/mouse). A–C: A fully alopecic female CRF-OE mouse before (A) and at 1 (B) and 4 weeks (C, with 90%
hair coverage), following the last sc astressin-B injection. D–F: A fully alopecic male mouse before (D) and at 1 (E) or 4 weeks (F) after the last sc
injection of astressin2-B, with no hair re-growth. G: Scores of skin pigmentation before the start of injection and 1 week after the last sc injection; H:
time course of hair growth score before and up to 4 weeks after last sc injection. Data are individual and median in G and mean 6 SEM in H. * p,0.05
vs week 0 (G and H); # p,0.05 vs astressin2-B at the corresponding week (G) and (H).
doi:10.1371/journal.pone.0016377.g003
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supported by the demonstration that although the short term
astressin-B treatment induced hair regrowth, it did not affect other
Cushing syndrome-like manifestations such as increased weights of
adrenal glands and abdominal fat deposits in CRF-OE.
One of the striking effects of astressin-B injected ip or sc was the
strong induction of skin/hair pigment within a few days following
the 5 days treatment regimen. Likewise, sc injection of the CRF2
receptor antagonist, astressin2-B induced a partial induction of skin
pigmentation and more so in young than alopecic CRF-OE mice at
one week after treatment. Hair pigment is under the control of
complex systems including neuroendocrine, neurotrophins, mela-
nocortin receptor signaling, melanin synthesis, and melanin
transport and incorporation to hair shaft keratinocytes [26,27].
Several factors, including CRF, POMC, ACTH and corticoids,
play a role in turning on or off the activity of hair follicle
melanocytes [27,28]. Interestingly, cutaneous melanocytes respond
to environmental stress such as UVB by the production of CRF
[29]. CRF1 and CRF2 receptors are differentially expressed and
exertdistinctfunctioninhumanandmurine hairfolliclepigmentary
units [6,8,30,31]. Urocortin 1, a mammalian member of CRF
peptide family with higher affinity to CRF2 receptor than CRF
down-regulates melanocyte differentiation phenotype [30]. The fact
that pigmentation occurred together with the induction of hair
growth in the astressin-B-treated mice is in agreement with the data
that melanogenesis is strictly coupled to anagen hair growth phase
[32]. Thus, CRF overexpression may suppress melanocyte activity,
whereas blockade of the CRF receptors by astressin-B turns on their
activity to cause skin/hair pigmentation. By contrast, inhibition of
CRF2 receptors by astressin2-B only partially stimulates activity.
Although a tremendous stride has been made in the understand-
ing of underlying cellular mechanisms of hair growth and alopecia,
there is a paucity of experimental models, particularly those
pertaining to chronic stress-related hair loss and their remedy. The
fact that the chronically stressed CRF-OE mice become alopecic in
adulthood is reminiscent of human hair loss associated with stress
[33]. Alopecia in the CRF-OE mice affects primarily, although is
not limited to, the back. Additionally, it is responsive to treatments
such as a non-selective, long acting CRF receptor antagonist, and to
a lesser extent to minoxidil, one of the few federally approved
clinical treatment of alopecia [21]. These findings suggest that the
alopecia in CRF-OE mice share some features as seen in humans.
The CRF-OE mice with sustained elevated levels of CRF and
corticosterone and hair loss as seen in the present and prior studies
[11] have good face and construct validity as a relevant model for
alopecia and therefore provide a unique opportunity to unravel
pathways in chronic stress-related hair loss.
Collectively, we have shown that peripheral blockade of the
CRF1 and CRF2 receptors with astressin-B injected peripherally
either subcutaneous or intraperitoneally for five consecutive days
at a dose as low as 5 mg/CRF-OE mouse activates skin
pigmentation and hair growth in alopecic mice and prevents hair
loss in young CRF-OE mice. Temporary blockade of the CRF
receptors could thus be a breakthrough therapy for alopecia
particularly for patients in acute (chemotherapy, traumatic
stressful events) or chronic stress setting. Moreover, the present
findings indicate that CRF-OE mice could be a relevant model to
advance our understanding of chronic stress-related hair loss.
Materials and Methods
Ethics Statement
The study involved the use of rodents. All experiments were
performed in accordance to relevant international and national
guidelines for use of laboratory animals. All procedures were
approved by the Veteran Affairs Greater Los Angeles Healthcare
System Animal Research Committees (Protocols 04012-06, 9906-
820 and 11084-03).
Mice
Male and female CRF-OE and wild type (WT) littermates were
derived from the transgenic line generated on C57BL/6 X SJL
Figure 4. Astressin-B injected intraperitoneally (ip) does not
influence plasma corticosterone (A), adrenal gland (B) and
visceral fat weights (C) in female CRF-OE mice (4–7 months
old). Each bar represents the mean 6 SEM (n=5/group or time point).
*p ,0.05 vs WT.
doi:10.1371/journal.pone.0016377.g004
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C57BL/6 as detailed previously using a chimeric CRF transgene
comprising the methallothionein-1 promoter driving the rat CRF
gene [11]. The mice were housed under controlled temperature
(21–23uC), humidity (30–35%) and light cycle (6:00 AM to 6:00
PM) and maintained on a standard rodent diet (Prolab RMH
2500, LabDiet, PMI Nutrition, Brentwood, MO).
Substances
Astressin-B and astressin2-B (Peptide Biology Laboratory, The
Salk Institute, La Jolla, CA) were synthesized using the solid phase
approach and the Boc-strategy as previously described [20,22] and
stored in powder form at 280uC. Immediately before the
experiments, peptides were dissolved in sterile water (pH 7.0).
NBI-27914 (Tocris, Ellisville MO) was dissolved in ethanol, Tween
80 and saline [1:0.5:8.5 (v/v), pH 5.0]. Minoxidil sulfate salt
(Sigma-Aldrich Co, St Louis, MN) was dissolved in 1:2:7 (v/v)
ethanol, polyethylene glycol and saline, respectively, pH 5.0.
Measurement of hair growth and pigmentation
The monitoring of hair growth was essentially as described by
Vegesna et al. [34]. Thus scores were made visually as well as
using photographs of each mouse at a weekly interval. Hair-
growth was observed in a dorsal region on the back of CRF-OE
mice that either fully developed alopecia (age $4 months) or not
yet developed alopecia (#8 weeks). The area was defined
anteriorly by a line joining the front base of the ears, posteriorly
by a line along the front of the pelvic girdle and laterally by the
lines projecting caudally from each ear base. A zero score
corresponded to a no change in the amount of hair in the test
alopecic area and the score of 10 to full hair growth in the entire
alopecic area. In brief, the percent area that is covered by hair in
the above-delimited area is scored between 0–10 to correspond to
hair coverage of 0–100% of the test region.
Pigmentation of the skin in the test region was also measured
because, in C57BL/6 mice, the skin darkens at the onset of hair
growth. A pigmentation score from 0–10 was given to each mouse
in the test region: 0: bright pink skin color/pigment; 1–5:
increasing intensity of a pale grayish color/pigment of skin; 6–9:
increasing but non-confluent darker color/pigment of skin; 10:
black pigmentation over the total test area. Pigmentation was
assessed one week after the final injection because changes (if any)
in pigmentation are substantially complete by that time.
Skin histology
CRF-OE and WT mice (male, 7 months old) injected ip with
saline or astressin-B (5 mg/mouse) for 5 consecutive days were
euthanized 2 weeks after the last injection with an overdose of
Figure 5. The CRF1/CRF2 receptor antagonist, astressin-B injected subcutaneously (sc) induces pigmentation and prevents hair loss
in young CRF-OE mice with not yet developed alopecia. Photos: representative CRF-OE female mice before injection (A, E) and the same mice
at 4, 8 and 16 weeks after astressin-B (B–C) or astressin2-B (F–H) injected sc once daily for 5 consecutive days at 5 mg/mice. Graph I: Individual and
median values of skin pigmentation scores before (week 0) and 1 week after the treatment. *: p,0.05 vs groups in week 0 and saline in week 1; #:
P,0.05 vs astressin2-B, Graph J: scores of hair growth before (week 0) and 1, 4, 8 and 16 weeks after the treatment. Each point represents the mean 6
SEM. *: p,0.05 vs week 0, before and after; #:p ,0.05 vs. astressin2-B or saline at the corresponding weeks.
doi:10.1371/journal.pone.0016377.g005
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Abbott Laboratories, Chicago, IL, USA) and skin samples were
obtained from the back (the alopecic area) and fixed in 4%
paraformaldehyde. Paraffin-embedded sections were processed for
hematoxylin/eosin staining and examined at light microscopy
(Zeiss Axioskp 2). Photomicrographs were acquired by a digital
camera (Hamamatsu, Bridgewater, NJ) using the image acquisi-
tion system SimplePCI (Hamamatsu Corporation, Sewickley, PA).
The length of hair follicle was measured using NIH Image J
version 1.42.
Plasma corticosterone levels, adrenal gland and visceral
fat weight determinations
CRF-OE mice and WT littermates (female, 4–7 months old)
were injected ip (0.1 ml) with astressin-B (5 mg/mouse) or saline
daily for 5 days and euthanized 7 days post last saline injection or
at day 1, 3, 7 or 14 after the last injection of astressin-B. Blood was
collected from the heart in less than a minute from mice
anesthetized with pentobarbital sodium (5 mg/0.1 ml/mouse,
ip). Plasma was immediately isolated and stored at 280uC until
assay. Plasma corticosterone levels were measured by Immuno-
chem I-125 corticosterone RIA kit (ICN Biomedical Inc., Costa
Mesa, CA). The assay was previously validated in mice [35,36]. At
day 7 post last injection, in addition to blood collection, adrenal
glands and visceral fat in the lower abdomen and pelvis were
harvested from CRF-OE and WT mice and weighed to the
nearest 0.1 mg.
Experimental protocols
(1) Treatment with CRF receptor antagonists in CRF-OE
mice with alopecia. The long-lasting peptide non-selective
CRF receptor antagonist, astressin-B, the selective CRF2 receptor
antagonist, astressin2-B [20,22] or sterile isotonic saline was
injected either ip or sc once a day for 5 days at 5 mg/0.1 ml/
mouse in female and male CRF-OE mice (4–9 months old) with
developed alopecia. The doses of astressin-B and astressin2-B were
chosen based on our previous studies in mice to antagonize
biological actions of ip CRF [22,25]. Pigmentation and hair
coverage scores were determined before the start of the first
injection and at 1, 4 and 8 weeks (for ip injection experiments) and
at 1, 2 and 4 weeks (for sc injection experiments) after the last
injection.
Figure 6. Effects of 1% minoxidil sulfate injected subcutaneously (sc) on alopecia in CRF-OE mice. Groups of 5 months old CRF-OE mice
were injected sc with either vehicle or minoxidil sulfate (1 mg/mouse) for 10 days. Hair growth score was monitored at 1, 2 and 4 weeks after the last
injection. A: scores of hair growth before (week 0) and at weeks 2 and 4 after the treatment. Each point represents the mean 6 SEM, n=5/group. B–E:
representative photos of CRF-OE mice before (B &D) and at 4 weeks after the last injection of vehicle (C) or minoxidil (F).
doi:10.1371/journal.pone.0016377.g006
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27914 (0.5 mg/mouse/injection) or its vehicle [1:0.5:8.5 (v/v) of
ethanol, Tween-80 and saline, pH 5.0] was injected sc in female
CRF-OE mice (5 months old) twice a day for 5 consecutive days.
The regimen of NBI-27914 was chosen based on our previous
studies [37]. Skin pigments and hair growth were monitored as in
experiments with sc injection of astressin-B.
(2) Prevention of alopecia with CRF receptor antagonists
in young CRF-OE mice with not yet developed
alopecia. Young female CRF-OE mice (7–8 weeks old) that
had not yet developed alopecia were injected sc with astressin-B,
astressin2-B, or saline, as described above. Littermate WT mice
served as control. Skin pigment and hair loss were monitored twice
a week in the first 2 weeks following the initial injection, once a
week up to 2 months, and monthly thereafter.
(3) Treatment of alopecia with minoxidil in CRF-OE
mice. Female CRF-OE mice (5 months old) received a daily sc
injection of 1% minoxidil sulfate (1 mg/mouse), or vehicle [1:2:7
(v/v) ethanol, polyethylene glycol and saline] for 10 consecutive
days. The regimen of minoxidil administration was selected from
previous studies showing facilitation of hair re-growth in another
model of alopecia [38]. Skin pigment and hair growth were
monitored as above following sc injection of astressin-B.
Statistical analysis
Results are expressed as mean 6 SEM or median. Comparisons
of hair growth responses before and after treatment in the same
animal were made using the before and after measure paired t-test
while skin pigment scores were analyzed using Mann-Whitney
rank sum test. Comparisons between different groups of hair
growth responses as well as plasma corticosterone, adrenals and
lower abdominal visceral fat weights were performed using either
One Way ANOVA followed by Student-Newman-Keuls Method
test or Student’s t-test to compare two groups mean values.
Differences in skin pigment between groups were compared using
Kruskal-Wallis One Way Analysis of Variance on Ranks. P,0.05
was considered significant.
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